Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong market demand in the peptide sector [1] Financial Performance - The expected revenue for 泰德医药 is projected to be between RMB 5.55 billion and RMB 5.85 billion, representing a year-on-year increase of approximately 25.5% to 32.3% [1] - The anticipated profit is estimated to be between RMB 2 billion and RMB 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Strategic Factors - Revenue growth is attributed to the successful execution of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company highlights its industry-leading project delivery timeliness and excellent project execution track record as key contributors to its performance [1] - There is a strong and growing demand from key clients for the company's services, driven by advancements in its research and development pipeline and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [1]

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by strategic initiatives and strong market demand in the peptide sector [1] Group 1: Financial Projections - The expected revenue for 泰德医药 is approximately RMB 5.55 billion to 5.85 billion, representing a year-on-year increase of about 25.5% to 32.3% [1] - The projected profit is estimated to be between RMB 2 billion and 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Group 2: Growth Drivers - Revenue growth is attributed to the successful implementation of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company has demonstrated industry-leading project delivery timeliness and excellent project execution track record, which has led to strong demand from key clients [1] - The expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is a significant factor contributing to the company's growth [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market [1] Financial Projections - The projected revenue for the fiscal year ending December 31, 2025, is approximately RMB 5.55 billion to RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The expected profit for the fiscal year ending December 31, 2025, is around RMB 2 billion to RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of RMB 592 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) for the fiscal year ending December 31, 2025, is projected to be about RMB 2 billion to RMB 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% compared to the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is primarily attributed to the successful implementation of the "follow-on molecule" strategy, the advantages of the company's integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform, and the strong demand from key clients due to advancements in their R&D pipelines [1] - The rapid expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is also a significant factor contributing to the anticipated growth [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market, particularly in the GLP-1 sector [1][2] Group 1: Revenue Projections - The company expects revenue for the fiscal year ending December 31, 2025, to be approximately RMB 5.55 billion to 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The revenue growth is attributed to the successful implementation of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] Group 2: Profit Projections - The company projects profit for the fiscal year ending December 31, 2025, to be around RMB 2 billion to 2.3 billion, which marks an increase of approximately 237.8% to 288.5% compared to the estimated profit of RMB 59.2 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) is expected to be about RMB 2 billion to 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% from the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Group 3: Factors Influencing Profit Growth - Profit growth is primarily driven by the aforementioned revenue increase, operational management optimization leading to cost savings and efficiency improvements, and fair value gains on financial liabilities recognized for the fiscal year ending December 31, 2025 [2] - The adjusted net profit increase is also attributed to revenue growth and operational efficiency enhancements [2]

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market, particularly in the GLP-1 sector [1][2]. Revenue Projections - The company expects revenue for the fiscal year ending December 31, 2025, to be approximately RMB 5.55 billion to 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of approximately RMB 4.42 billion for the fiscal year ending December 31, 2024 [1]. - The revenue growth is attributed to the successful implementation of the "follow-on" strategy and the advantages of the integrated contract research, development, and manufacturing organization (CRDMO) platform [1]. Profit Projections - The company projects profit for the fiscal year ending December 31, 2025, to be approximately RMB 2 billion to 2.3 billion, which marks an increase of about 237.8% to 288.5% compared to the estimated profit of approximately RMB 59.2 million for the fiscal year ending December 31, 2024 [1]. - The adjusted net profit (non-IFRS) is expected to be around RMB 2 billion to 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% from the estimated adjusted net profit of about RMB 1.72 billion for the fiscal year ending December 31, 2024 [1]. Factors Influencing Profit Growth - Profit growth is primarily driven by the aforementioned revenue increase, operational management optimization leading to cost savings and efficiency improvements, and fair value gains on financial liabilities recognized for the fiscal year ending December 31, 2025 [2]. - The adjusted net profit increase is also attributed to revenue growth and operational efficiency enhancements [2].

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by strategic initiatives and strong demand in the peptide market [1][2]. Revenue Forecast - The company expects revenue for the fiscal year 2025 to be between approximately RMB 5.55 billion and RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of approximately RMB 4.422 billion for 2024 [1]. Profit Forecast - The anticipated profit for 2025 is projected to be between approximately RMB 2 billion and RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of around RMB 592 million for 2024 [1]. Adjusted Net Profit Forecast - The adjusted net profit for 2025 is expected to range from approximately RMB 2 billion to RMB 2.3 billion, reflecting an increase of about 16.3% to 33.7% compared to the adjusted net profit of approximately RMB 1.72 billion for 2024 [1]. Factors Driving Revenue Growth - Revenue growth is attributed to the successful implementation of the "follow-on" strategy, the advantages of the integrated contract research, development, and manufacturing organization (CRDMO) platform, timely project delivery, and strong demand from key clients due to advancements in their R&D pipelines and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [2]. Factors Driving Profit Growth - Profit growth is influenced by the aforementioned revenue increase, cost savings and efficiency improvements achieved through optimized operational management, and fair value gains from financial liabilities recognized in 2025, which contrasts with the fair value losses recorded in 2024 [2]. Factors Driving Adjusted Net Profit Growth - The increase in adjusted net profit is primarily due to the revenue growth and the comprehensive impact of cost savings and efficiency improvements from optimized operational management [2].